Pedro Gonzales1, Chethan Bachireddy2,3, Arielle Grieco4, Rona Ding4, Samy J Galvez de Leon5, Angela Ulrich4,6, Javier Lama1,4, Ann C Duerr4, Frederick L Altice5,7. 1. Asociación Civil Impacta Salud y Educación, Lima, Peru. 2. Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA. 3. Leonard Davis Institute Center for Health Incentives and Behavioral Economics, Philadelphia, PA. 4. Vaccine and Infectious Disease and Public Health Science Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA. 5. Department of Medicine, Yale School of Medicine, Section of Infectious Diseases, New Haven, CT; and. 6. Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN. 7. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT.
Abstract
BACKGROUND: Alcohol use disorders (AUDs) are common in men who have sex with men (MSM) and transgender women (TGW) in Peru and undermine antiretroviral therapy (ART) adherence. Oral naltrexone (NTX) is an evidence-based treatment for AUD that has not been assessed in cotreating AUD in MSM/TGW with HIV. SETTING AND DESIGN: A multi-site, randomized, double-blind, placebo-controlled trial among MSM/TGW with AUD and newly diagnosed with HIV in Lima, Peru. METHODS: Newly diagnosed MSM/TGW with HIV and AUD were prescribed a single-treatment regimen of EFV/TDF/FTC from 2014 to 2015 and randomized 2:1 to oral NTX (N = 103) or placebo (N = 53) for 24 weeks. The primary and secondary outcomes were proportion achieving viral suppression (VS: HIV-1 RNA < 400 copies/mL) or maximal viral suppression (MVS: HIV-1 RNA < 40 copies/mL) at 24 weeks. RESULTS: There were no significant differences between the arms in VS (81.6% NTX arm vs 75.5% placebo arm; P = 0.37) or MVS (61.2% NTX arm vs 66.0% placebo arm; P = 0.48). Adherence to study medication was low (mean = 34.6%) overall with only 21.4% of participants meeting recommended adherence levels (≥80% daily doses/month). Participants allocated to NTX had significantly lower adherence compared with placebo for both the first and second 12-week study periods, respectively (44.0% vs 35.2%, P = 0.04; 31.4% vs 35.2%, P = 0.03). CONCLUSIONS: Findings are inconclusive regarding the use of NTX for treatment of AUD in MSM/TGW newly diagnosed with HIV. VS and MVS levels were high irrespective of allocation. Adherence to study medication was low, requiring further exploration of strategies to optimize adherence to NTX as AUD treatment.
BACKGROUND: Alcohol use disorders (AUDs) are common in men who have sex with men (MSM) and transgender women (TGW) in Peru and undermine antiretroviral therapy (ART) adherence. Oral naltrexone (NTX) is an evidence-based treatment for AUD that has not been assessed in cotreating AUD in MSM/TGW with HIV. SETTING AND DESIGN: A multi-site, randomized, double-blind, placebo-controlled trial among MSM/TGW with AUD and newly diagnosed with HIV in Lima, Peru. METHODS: Newly diagnosed MSM/TGW with HIV and AUD were prescribed a single-treatment regimen of EFV/TDF/FTC from 2014 to 2015 and randomized 2:1 to oral NTX (N = 103) or placebo (N = 53) for 24 weeks. The primary and secondary outcomes were proportion achieving viral suppression (VS: HIV-1 RNA < 400 copies/mL) or maximal viral suppression (MVS: HIV-1 RNA < 40 copies/mL) at 24 weeks. RESULTS: There were no significant differences between the arms in VS (81.6% NTX arm vs 75.5% placebo arm; P = 0.37) or MVS (61.2% NTX arm vs 66.0% placebo arm; P = 0.48). Adherence to study medication was low (mean = 34.6%) overall with only 21.4% of participants meeting recommended adherence levels (≥80% daily doses/month). Participants allocated to NTX had significantly lower adherence compared with placebo for both the first and second 12-week study periods, respectively (44.0% vs 35.2%, P = 0.04; 31.4% vs 35.2%, P = 0.03). CONCLUSIONS: Findings are inconclusive regarding the use of NTX for treatment of AUD in MSM/TGW newly diagnosed with HIV. VS and MVS levels were high irrespective of allocation. Adherence to study medication was low, requiring further exploration of strategies to optimize adherence to NTX as AUD treatment.
Authors: Sandra A Springer; Angela Di Paola; Russell Barbour; Marwan M Azar; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Hae Kook Lee; S Patricia Chou; Maeng Je Cho; Jong-Ik Park; Deborah A Dawson; Bridget F Grant Journal: Alcohol Date: 2010-05-31 Impact factor: 2.405
Authors: Katherine M Rich; Jeffrey A Wickersham; Javier Valencia Huamaní; Sara N Kiani; Robinson Cabello; Paul Elish; Jorge Florez Arce; Lia N Pizzicato; Jaime Soria; Jorge Sanchez; Frederick L Altice Journal: LGBT Health Date: 2018 Nov/Dec Impact factor: 4.151
Authors: Mark A Marzinke; Beatriz Grinsztejn; Jessica M Fogel; Estelle Piwowar-Manning; Maoji Li; Lei Weng; Marybeth McCauley; Vanessa Cummings; Shahnaz Ahmed; Casey D Haines; Lane R Bushman; Christos Petropoulos; Deborah Persaud; Adeola Adeyeye; Ryan Kofron; Alex Rinehart; Marty St Clair; James F Rooney; Daniel Pryluka; Lara Coelho; Aditya Gaur; Keren Middelkoop; Nittaya Phanuphak; Myron S Cohen; Craig W Hendrix; Peter Anderson; Brett Hanscom; Deborah Donnell; Raphael J Landovitz; Susan H Eshleman Journal: J Infect Dis Date: 2021-11-16 Impact factor: 7.759
Authors: Juliana de Oliveira Costa; Maria das Graças Braga Ceccato; Micheline Rosa Silveira; Palmira de Fátima Bonolo; Edna Afonso Reis; Francisco de Assis Acurcio Journal: Rev Saude Publica Date: 2018-11-14 Impact factor: 2.106
Authors: Pedro Gonzales; Arielle Grieco; Edward White; Rona Ding; Rachel Bender Ignacio; Delia Pinto-Santini; Javier R Lama; Frederick L Altice; Ann Duerr Journal: PLoS One Date: 2020-03-05 Impact factor: 3.240